Brief: Hansa Biopharma: NICE Recommends Use Of Idefirix (Imlifidase) As Desensitization Treatment
16/06/2022 06:07
June 16 (Reuters) - Hansa Biopharma AB HNSA.ST :
* NICE RECOMMENDS USE OF HANSA BIOPHARMA'S IDEFIRIX®
(IMLIFIDASE)
AS DESENSITIZATION TREATMENT FOR HIGHLY SENSITIZED KIDNEY
TRANSPLANT PATIENTS
Source text for Eikon: ID:nWkr5b1tCB
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS